33 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
9 May 24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
4:20pm
Financial Results
As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.
Research and development (R&D) expenses were $3.1 million … million increase in our preclinical expenses and a $0.2 million increase in internal research and development expenses.
General and administrative
8-K
EX-99.1
ma4ssq35yu
19 Mar 24
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
8:21am
424B3
i344 hcyz
16 Jan 24
Prospectus supplement
4:06pm
S-3
mbp0 m46h
4 Jan 24
Shelf registration
4:46pm
8-K
EX-99.1
3i9eb
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
8-K
EX-99.1
zvn3eu5 2bgxozkgc
8 Aug 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
7:05am
DEF 14A
6app4k4
19 May 23
Definitive proxy
4:31pm
10-Q
axjz 1o1q9yxks
10 May 23
Quarterly report
7:14am
10-Q
EX-10.1
cqg sxywhoipwt5c2
10 May 23
Quarterly report
7:14am
8-K
EX-99.1
kf0jt
10 May 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
7:11am
10-K
tzbuhpo5
29 Mar 23
Annual report
4:08pm
424B4
fhn4heuylu
30 Dec 22
Prospectus supplement with pricing info
4:17pm
CORRESP
7ot wo1s3
13 Dec 22
Correspondence with SEC
12:00am